Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

GLOBAL: Roche Adds HIV Blindness Drug to Patent Pool, Cutting Price


Reuters (08.05.2013) Aids Weekly Plus

On August 5, drug manufacturer Roche agreed to lower the price and pool intellectual property rights on its oral drug valganciclovir, which is used to treat cytomegalovirus (CMV), making the drug potentially up to 90 percent cheaper in 138 developing countries. CMV is a viral infection that can cause blindness in people with HIV. The Swiss drug maker completed negotiations with the new Medicines Patent Pool (MPP), which is attempting to convince major drug manufacturers to share rights to important medicines that could greatly benefit developing countries with those who manufacture cheaper generic drugs. Currently, the most widely used treatment for CMV in developing countries involves injections directly into the eye, which can be painful and difficult to give. MPP’s agreement with Roche followed HIV treatment drug agreements made with Gilead Sciences and ViiV Healthcare, which is majority-owned by GlaxoSmithKline. The UNITAID health financing system launched the UN-backed MPP in 2010.


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in August 6, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.